Cingulate Inc.: peers
Cingulate Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Climb Bio, Inc., Kyntra Bio, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Cingulate Inc.base CING · 🇺🇸 US Percentile in Healthcare Percentile in USA | Neumora Therapeutics, Inc. NMRA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Tenax Therapeutics, Inc. TENX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Climb Bio, Inc. CLYM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Kyntra Bio, Inc. KYNB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nutriband Inc. NTRB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Telomir Pharmaceuticals, Inc. TELO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Rallybio Corporation RLYB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $83 MOct 28, 2026 · Market data4th of 8 | $81 MOct 16, 2026 · Market data5th of 8 | $86 MOct 29, 2026 · Market data3rd of 8 | $80 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $79 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $79 MOct 29, 2026 · Market data8th of 8 | $88 MOct 7, 2026 · Market data1st of 8 | $88 MOct 27, 2026 · Market data2nd of 8 | $82 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | —— | $6 MFY2025 · SEC1st of 3 | $2 MFY2025 · SEC2nd of 3 | —— | $1 MFY2025 · SEC3rd of 3 | $2 M3 ranked |
| Net income (Higher is better) | $-22 MFY2025 · SEC5th of 8 | $-237 MFY2025 · SEC8th of 8 | $-53 MFY2025 · SEC6th of 8 | $-60 MFY2025 · SEC7th of 8 | $183 MFY2025 · SEC1st of 8 | $-8 MFY2025 · SEC2nd of 8 | $-10 MFY2025 · SEC4th of 8 | $-9 MFY2025 · SEC3rd of 8 | $-16 M8 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | 14December 31, 2025 · Profile3rd of 4 | 28December 31, 2025 · Profile2nd of 4 | 566As on 2021 · Profile1st of 4 | —— | —— | 14December 31, 2025 · Profile3rd of 4 | 214 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | -78.3%FY2025 · SEC2nd of 21st0th | -4.7%FY2025 · SEC1st of 218th18th | ———— | ———— | -41.5%2 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | -64.2%FY2025 · SEC2nd of 20th0th | -0.7%FY2025 · SEC1st of 225th30th | ———— | ———— | -32.4%2 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | ———— | 91.3%FY2025 · SEC1st of 293rd97th | 27.9%FY2025 · SEC2nd of 214th31st | ———— | ———— | 59.6%2 ranked |
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | -712.7%FY2025 · SEC2nd of 23rd1st | -407.8%FY2025 · SEC1st of 28th3rd | ———— | ———— | -560.3%2 ranked |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | -403.4%FY2025 · SEConly one with it8th3rd | ———— | ———— | -403.4%— |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | -74.7%FY2025 · SEC1st of 224th10th | -252.0%FY2025 · SEC2nd of 213th4th | ———— | ———— | -163.3%2 ranked |
| Return on equity (Higher is better) | -450.4%FY2025 · SEC7th of 72nd1st | -121.2%FY2025 · SEC4th of 720th9th | -55.6%FY2025 · SEC3rd of 740th17th | -32.1%FY2025 · SEC2nd of 753rd23rd | ———— | -125.5%FY2025 · SEC5th of 719th8th | -317.9%FY2025 · SEC6th of 74th2nd | -15.0%FY2025 · SEC1st of 763rd30th | -121.2%7 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | 48.7×price Oct 29, 2026 · Market data2nd of 291st97th | ———— | 102.8×price Oct 27, 2026 · Market data1st of 295th98th | 75.7×2 ranked |
| Price to book (Better neither way: ranked highest first) | 33.0×price Oct 28, 2026 · Market data1st of 695th97th | 0.8×price Oct 16, 2026 · Market data6th of 615th14th | 0.9×price Oct 29, 2026 · Market data5th of 617th17th | ———— | ———— | 11.8×price Oct 29, 2026 · Market data3rd of 687th91st | 15.0×price Oct 7, 2026 · Market data2nd of 690th94th | 1.5×price Oct 27, 2026 · Market data4th of 631st37th | 6.7×6 ranked |
| Free cash flow yield (Higher is better) | -21.0%price Oct 28, 2026 · Market data3rd of 432nd14th | ———— | -13.3%price Oct 29, 2026 · Market data2nd of 438th18th | ———— | ———— | -6.5%price Oct 29, 2026 · Market data1st of 450th25th | ———— | -55.8%price Oct 27, 2026 · Market data4th of 417th7th | -17.2%4 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | 0.5×FY2025 · SEConly one with it54th46th | ———— | ———— | ———— | ———— | ———— | ———— | 0.5×— |
| Interest cover (Higher is better) | -22.2×FY2025 · SEC2nd of 431st15th | -120.0×FY2025 · SEC3rd of 413th5th | ———— | ———— | -5.2×FY2025 · SEC1st of 454th29th | -416.0×FY2025 · SEC4th of 47th2nd | ———— | ———— | -71.1×4 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 1 of 13FY2025 · Scorecard8th of 8 | 4 of 12FY2025 · Scorecard2nd of 8 | 2 of 12FY2025 · Scorecard4th of 8 | 1 of 8FY2025 · Scorecard6th of 8 | 5 of 14FY2025 · Scorecard1st of 8 | 3 of 21FY2025 · Scorecard5th of 8 | 1 of 9FY2025 · Scorecard7th of 8 | 4 of 12FY2025 · Scorecard2nd of 8 | 15% passed8 ranked |
| Valuation checks (Higher is better) | 0 of 4FY2025 · Scorecard4th of 6 | 1 of 3FY2025 · Scorecard1st of 6 | 1 of 4FY2025 · Scorecard3rd of 6 | —— | —— | 0 of 5FY2025 · Scorecard4th of 6 | 0 of 3FY2025 · Scorecard4th of 6 | 1 of 3FY2025 · Scorecard1st of 6 | 13% passed6 ranked |
| Growth checks (Higher is better) | 0 of 2FY2025 · Scorecard4th of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 0 of 2FY2025 · Scorecard4th of 8 | 0 of 2FY2025 · Scorecard4th of 8 | 2 of 6FY2025 · Scorecard2nd of 8 | 1 of 6FY2025 · Scorecard3rd of 8 | 0 of 1FY2025 · Scorecard4th of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 0% passed8 ranked |
| Profitability checks (Higher is better) | 0 of 3FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 1 of 4FY2025 · Scorecard1st of 8 | 0 of 5FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 0% passed8 ranked |
| Financial health checks (Higher is better) | 1 of 3FY2025 · Scorecard7th of 8 | 3 of 5FY2025 · Scorecard2nd of 8 | 1 of 2FY2025 · Scorecard3rd of 8 | 1 of 2FY2025 · Scorecard3rd of 8 | 1 of 3FY2025 · Scorecard7th of 8 | 2 of 4FY2025 · Scorecard3rd of 8 | 1 of 2FY2025 · Scorecard3rd of 8 | 2 of 3FY2025 · Scorecard1st of 8 | 50% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 0 of 1FY2025 · Scorecard2nd of 8 | 0% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 19.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 62.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 70.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 110.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 26.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 3.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 4.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 68.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 44.2%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 412026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 1272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 1062026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 1282026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 352026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 262026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 388 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +2.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +1.8 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | -45.0 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +41.7 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | -0.9 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | -0.2 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | -2.2 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +88.0 pp2026-Q1 against 2025-Q4 · 13F1st of 8 | +0.8 pp8 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cingulate Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Neumora Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tenax Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Climb Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Kyntra Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nutriband Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Telomir Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Rallybio Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Cingulate Inc. | — | — | — |
| Neumora Therapeutics, Inc. | — | — | — |
| Tenax Therapeutics, Inc. | — | — | — |
| Climb Bio, Inc. | — | — | — |
| Kyntra Bio, Inc. | -712.7%FY2025 | 3rd percentile in Healthcaremedian -7.7%, 674 companies | 1st percentile in USAmedian 3.5%, 2,594 companies |
| Nutriband Inc. | -407.8%FY2025 | 8th percentile in Healthcaremedian -7.7%, 674 companies | 3rd percentile in USAmedian 3.5%, 2,594 companies |
| Telomir Pharmaceuticals, Inc. | — | — | — |
| Rallybio Corporation | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Cingulate Inc. | Neumora Therapeutics, Inc. | Tenax Therapeutics, Inc. | Climb Bio, Inc. | Kyntra Bio, Inc. | Nutriband Inc. | Telomir Pharmaceuticals, Inc. | Rallybio Corporation |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | $6 MSEC1st | $2 MSEC2nd | — | $1 MSEC3rd |
| 2024 | — | — | — | — | $30 MSEC1st | $2 MSEC2nd | — | $1 MSEC3rd |
| 2023 | — | — | — | — | $47 MSEC1st | $2 MSEC2nd | — | — |
| 2022 | — | — | — | — | $141 MSEC1st | $2 MSEC2nd | — | — |
| 2021 | — | — | — | — | $235 MSEC1st | $1 MSEC2nd | — | — |
| 2020 | — | — | — | — | $176 MSEC1st | $1 MSEC2nd | — | — |
| 2019 | — | — | — | — | $257 MSEC1st | $0 MSEC2nd | — | — |
| 2018 | — | — | — | — | $213 MSEC1st | $0 MSEC2nd | — | — |
| 2017 | — | — | — | — | $131 MSEC | — | — | — |
| 2016 | — | — | — | — | $183 MSEC | — | — | — |
| 2015 | — | — | — | — | $181 MSEC | — | — | — |
| 2014 | — | — | $0 MSEC2nd | — | $138 MSEC1st | — | — | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Cingulate Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Neumora Therapeutics, Inc.NMRA · 🇺🇸 USASame industry: Biotechnology · Similar size: $81 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $81 M (Oct 16, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Tenax Therapeutics, Inc.TENX · 🇺🇸 USASame industry: Biotechnology · Similar size: $86 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $86 M (Oct 29, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Climb Bio, Inc.CLYM · 🇺🇸 USASame industry: Biotechnology · Similar size: $80 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $80 M (last known, Jan 5, 2024)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Kyntra Bio, Inc.KYNB · 🇺🇸 USASame industry: Biotechnology · Similar size: $79 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $79 M (last known, Jan 5, 2024) · revenue $6 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Nutriband Inc.NTRB · 🇺🇸 USASame industry: Biotechnology · Similar size: $79 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $79 M (Oct 29, 2026) · revenue $2 M (year to January 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Telomir Pharmaceuticals, Inc.TELO · 🇺🇸 USASame industry: Biotechnology · Similar size: $88 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $88 M (Oct 7, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Rallybio CorporationRLYB · 🇺🇸 USASame industry: Biotechnology · Similar size: $88 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $88 M (Oct 27, 2026) · revenue $1 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Acrivon Therapeutics, Inc.ACRV · 🇺🇸 USASame industry: Biotechnology · Similar size: $77 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $77 M (Oct 21, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- NeOnc Technologies Holdings, Inc.NTHI · 🇺🇸 USASame industry: Biotechnology · Similar size: $90 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $90 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Verrica Pharmaceuticals Inc.VRCA · 🇺🇸 USASame industry: Biotechnology · Similar size: $76 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $76 M (Sep 21, 2026) · revenue $36 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Tenaya Therapeutics, Inc.TNYA · 🇺🇸 USASame industry: Biotechnology · Similar size: $91 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $91 M (Oct 28, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Coya Therapeutics, Inc.COYA · 🇺🇸 USASame industry: Biotechnology · Similar size: $92 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $92 M (Oct 26, 2026) · revenue $8 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.